L&G Pharma Breakthrough UCITS ETF (BIGT)
Category Sector Equity Biotechnology
This ETF can be held in an Investment ISA, SIPP and Investment Account
Sell
801.80p
Buy
804.80p
6.55p (+0.82%)
Prices updated at 26 Sep 2024, 16:16 BST
| Prices minimum 15 mins delay
Prices in GBX
Investment objective
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Price
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk profile
- Management
Portfolio as of 25/09/2024
Asset allocation
Show long & short position
Geographical breakdown
Continent or country allocation (%)
Market classification (%)
Stock style
Small core
18.74%
% Weight
Value
Core
Growth
Large
5
13
16
Medium
8
6
16
Small
3
19
14
Valuation
L&G Pharma Breakthrough UCITS ETF
Sector Equity Biotechnology
19.27
2.97
2.40
11.03
Growth rate
L&G Pharma Breakthrough UCITS ETF
Sector Equity Biotechnology
19.79%
1.03%
-8.59%
Top 10 holdings
1
Pharma Mar SA
Sector
-
Country
Spain
% of assets
3.12576
2
LG Chem Ltd
Sector
-
Country
South Korea
% of assets
3.04123
3
Agios Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
3.0341
4
Alnylam Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
3.01196
5
Xeris Biopharma Holdings Inc
Sector
-
Country
United States
% of assets
2.99765
6
BeiGene Ltd ADR
Sector
-
Country
China
% of assets
2.94499
7
Nippon Shinyaku Co Ltd
Sector
-
Country
Japan
% of assets
2.90641
8
Swedish Orphan Biovitrum AB
Sector
-
Country
Sweden
% of assets
2.88437
9
Chugai Pharmaceutical Co Ltd
Sector
-
Country
Japan
% of assets
2.86003
10
InnoCare Pharma Ltd
Sector
-
Country
China
% of assets
2.85016
Assets in top 10 holdings %
29.66%
Total no. of equity holdings
37.00
Total no. of bond holdings
-
Stock sectors
L&G Pharma Breakthrough UCITS ETF
Sector Equity Biotechnology
3.04%
Basic materials
Con cyclical
Financial svs
Real estate
0.00%
Comm services
Energy
Industrials
Technology
96.96%
Con defensive
Healthcare
Utilities